Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction of NVP-1603-1 and NVP-1603-2 in Healthy Men
NCT03220399Phase 1Withdrawn
- Sponsor
- NVP Healthcare Co., Ltd.
- Start
- Dec 2019
- Primary completion
- Mar 2020
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of NVP-1603-2 in nervous system disease (3 arms), sponsored by NVP Healthcare Co., Ltd. Primary endpoint: Pharmacokinetic interaction (AUC). Planned start Dec 2019; status: withdrawn.
02
Drugs
NVP-1603-2
03
Conditions
nervous system disease
Beyond the preview
Go deeper on NCT03220399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03220399.